Ovid Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Ovid Therapeutics CEO'su Meg Alexander, Sep2024 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 1.02M olup, şirket hissesi ve opsiyonları dahil olmak üzere 50.4% maaş ve 49.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.033% ine doğrudan sahiptir ve bu hisseler $ 143.90K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.4 yıl ve 3.7 yıldır.
Anahtar bilgiler
Meg Alexander
İcra Kurulu Başkanı
US$1.0m
Toplam tazminat
| CEO maaş yüzdesi | 50.38% |
| CEO görev süresi | 1.9yrs |
| CEO sahipliği | 0.03% |
| Yönetim ortalama görev süresi | 1.4yrs |
| Yönetim Kurulu ortalama görev süresi | 3.7yrs |
Son yönetim güncellemeleri
Recent updates
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook
Analysts have raised their price target on Ovid Therapeutics stock from $5 to $7, citing updated cash flow models that now factor in potential revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the start of a Phase 1 study of OV4071. What's in the News for Ovid Therapeutics Ovid Therapeutics added to the S&P Biotechnology Select Industry Index, reflecting inclusion in a widely followed biotech industry benchmark.Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Summary Ovid Therapeutics receives a "Hold" rating as it pivots pipeline focus after soticlestat trial failures in rare epileptic syndromes. OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset seizures, with phase 2a trials planned for 2026. Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026. Recent financing extends OVID's cash runway into 2028, but clinical and regulatory risks remain for OVID's early-stage programs. Read the full article on Seeking AlphaOvid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024. The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030. Read the full article on Seeking AlphaWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Ovid Therapeutics press release (NASDAQ:OVID): Q2 GAAP EPS of -$0.21 beats by $0.04. Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 millionWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Ovid Therapeutics Inc.'s...Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Ovid Therapeutics Inc. ( NASDAQ:OVID ) shareholders will have a reason to smile today, with the analysts making...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$24m |
| Dec 31 2025 | US$1m | US$515k | -US$17m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$24m |
| Dec 31 2024 | US$2m | US$484k | -US$26m |
Tazminat ve Piyasa: Meg 'nin toplam tazminatı ($USD 1.02M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.41M ).
Tazminat ve Kazançlar: Meg 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Meg Alexander (45 yo)
Ms. Margaret Alexander, also known as Meg, is CEO of Ovid Therapeutics Inc. from January 1, 2026 and serves as its President since September 2024 and served as Chief Strategy Officer since June 2023 until...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.3yrs | US$1.93m | 2.02% $ 8.8m | |
| CEO, President & Director | 1.9yrs | US$1.02m | 0.033% $ 143.9k | |
| Advisor | less than a year | US$969.16k | 0.085% $ 370.0k | |
| CFO, Principal Financial Officer | less than a year | Veri yok | 0.0054% $ 23.3k | |
| Chief Scientific Officer | 3.2yrs | Veri yok | Veri yok | |
| Senior Vice President of Clinical Development | 5.1yrs | Veri yok | Veri yok | |
| Head of Epilepsy Research | 3.5yrs | Veri yok | Veri yok | |
| Chief Regulatory Officer | 1.4yrs | Veri yok | Veri yok | |
| Chief Strategy Officer | 1.4yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok | |
| Chief Business Officer | less than a year | Veri yok | Veri yok | |
| Vice President of Research and Early Development | no data | Veri yok | Veri yok |
Deneyimli Yönetim: OVID 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.4 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.3yrs | US$1.93m | 2.02% $ 8.8m | |
| CEO, President & Director | less than a year | US$1.02m | 0.033% $ 143.9k | |
| Chairman of the Scientific & Clinical Advisory Board | 5.3yrs | Veri yok | Veri yok | |
| Independent Director | 9.2yrs | US$86.27k | 0% $ 0 | |
| Lead Independent Director | 10.8yrs | US$105.75k | 0.0047% $ 20.5k | |
| Member of Scientific & Clinical Advisory Board | 9.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.1yrs | Veri yok | Veri yok | |
| Independent Director | 4.8yrs | US$69.94k | 0.0094% $ 41.0k | |
| Member of Scientific Advisory Board | 2.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.6yrs | Veri yok | Veri yok |
Deneyimli Yönetim Kurulu: OVID 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/04 11:17 |
| Gün Sonu Hisse Fiyatı | 2026/08/03 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ovid Therapeutics Inc. 16 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |